Skip to main content
. 2022 Jun 30;8(8):1169–1176. doi: 10.1001/jamaoncol.2022.2253

Figure 2. Progression-Free Survival (PFS) and Overall Survival (OS).

Figure 2.

Kaplan-Meier analysis of PFS (A) and OS (B) in the intent-to-treat population. Stratification factors included platinum-free interval (≤3 months vs 3-6 months) and prior platinum-sensitive relapse (yes vs no). HR indicates hazard ratio; NR, not reached; PLD, pegylated liposomal doxorubicin.